Vanda Pharmaceuticals (VNDA) News Today $4.60 -0.17 (-3.56%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$4.60 0.00 (-0.11%) As of 03/27/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Vanda Pharmaceuticals’ New Drug Application Accepted by FDAMarch 17, 2025 | tipranks.comVNDA Vanda Pharmaceuticals Inc.March 15, 2025 | seekingalpha.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Monaco Asset Management SAMMonaco Asset Management SAM increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 92.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 392,262 shares of the biopharmaceutical company'sMarch 15, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Shares Pass Above 200-Day Moving Average - Here's What HappenedVanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average - Should You Sell?March 13, 2025 | marketbeat.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 10,000 Shares of StockVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the purchase, the chief executive officer now owns 2,285,731 shares in the company, valued at $11,474,369.62. This trade represents a 0.44 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.March 6, 2025 | marketbeat.comInsider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)March 5, 2025 | gurufocus.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Buys 10,000 Shares of StockVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the transaction, the chief executive officer now owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This represents a 0.43 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.March 1, 2025 | marketbeat.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of StockMarch 1, 2025 | insidertrades.comInsider Buying: Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc (VNDA)March 1, 2025 | gurufocus.comInsider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)February 27, 2025 | gurufocus.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Acquires 10,000 SharesVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were bought at an average price of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This trade represents a 0.43 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.February 26, 2025 | marketbeat.comVanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $47,650 in stockFebruary 26, 2025 | investing.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC decreased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 51.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 73,858 shares of the biopharmaceutical company'sFebruary 26, 2025 | marketbeat.comVanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"February 24, 2025 | prnewswire.comQ1 EPS Forecast for Vanda Pharmaceuticals Lowered by AnalystVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Equities research analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Vanda Pharmaceuticals in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates thaFebruary 21, 2025 | marketbeat.comQ1 Earnings Forecast for VNDA Issued By HC WainwrightVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a report released on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical comFebruary 20, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Vanda Pharmaceuticals (NASDAQ:VNDA) Stock PriceHC Wainwright lifted their price objective on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday.February 19, 2025 | marketbeat.comThe Analyst Verdict: Vanda Pharma In The Eyes Of 5 ExpertsFebruary 19, 2025 | benzinga.comVanda Pharmaceuticals price target raised to $20 from $18 at H.C. WainwrightFebruary 19, 2025 | markets.businessinsider.comVanda (VNDA) Gets a Buy from H.C. WainwrightFebruary 19, 2025 | markets.businessinsider.comVanda Pharmaceuticals' SWOT analysis: deep value play amid pipeline growthFebruary 17, 2025 | msn.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2024 Earnings Call TranscriptFebruary 15, 2025 | insidermonkey.comQ4 2024 Vanda Pharmaceuticals Inc Earnings CallFebruary 14, 2025 | uk.finance.yahoo.comVanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPSVanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%.February 14, 2025 | marketbeat.comVanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst ChallengesFebruary 14, 2025 | gurufocus.comQ4 2024 Vanda Pharmaceuticals Inc Earnings Call TranscriptFebruary 14, 2025 | gurufocus.comVanda Pharmaceuticals targets $1B revenue by 2030 with expanded psychiatry portfolioFebruary 13, 2025 | msn.comVanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comVanda Pharmaceuticals targets total annual revenue in excess of $1B in 2030February 13, 2025 | markets.businessinsider.comVanda Pharmaceuticals sees FY25 revenue $210M-$250M, consensus $284.9MFebruary 13, 2025 | markets.businessinsider.comVanda Pharmaceuticals Q4 2024 Earnings: EPS Loss of $0. ...February 13, 2025 | gurufocus.comVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 13, 2025 | prnewswire.comBlackRock, Inc. Reduces Stake in Vanda Pharmaceuticals Inc.February 7, 2025 | gurufocus.comVanda Pharmaceuticals (VNDA) Projected to Post Earnings on ThursdayVanda Pharmaceuticals (NASDAQ:VNDA) will be releasing earnings before the market opens on Thursday, February 13.February 7, 2025 | marketbeat.comVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025February 5, 2025 | prnewswire.comBlackRock, Inc. Increases Stake in Vanda Pharmaceuticals Inc.February 5, 2025 | gurufocus.comVanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.comStockNews.com started coverage on Vanda Pharmaceuticals in a research note on Wednesday. They set a "hold" rating on the stock.February 5, 2025 | marketbeat.comAnaptysBio, Vanda announce exclusive global license agreement for VandaFebruary 4, 2025 | markets.businessinsider.comVanda Pharmaceuticals and AnaptysBio to develop and market imsidolimabFebruary 4, 2025 | markets.businessinsider.comVanda stock holds Buy rating, $18 target from H.C. WainwrightFebruary 4, 2025 | msn.comHC Wainwright Reaffirms Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday.February 4, 2025 | marketbeat.comVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to ...February 3, 2025 | gurufocus.comVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to ...February 3, 2025 | gurufocus.comVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R AntagonistFebruary 3, 2025 | prnewswire.comVanda Pharmaceuticals (VNDA) Projected to Post Earnings on WednesdayVanda Pharmaceuticals (NASDAQ:VNDA) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comH.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stockJanuary 29, 2025 | msn.comA Glimpse Into The Expert Outlook On Vanda Pharma Through 4 AnalystsJanuary 29, 2025 | benzinga.comVanda Pharmaceuticals: Buy Rating Affirmed Amidst Pipeline Progress and Strategic ExpansionJanuary 29, 2025 | markets.businessinsider.comVanda Pharmaceuticals' (VNDA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday.January 28, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.comStockNews.com started coverage on shares of Vanda Pharmaceuticals in a research report on Tuesday. They issued a "hold" rating for the company.January 28, 2025 | marketbeat.com Remove Ads Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Media Mentions By Week VNDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼1.890.78▲Average Medical News Sentiment VNDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼14▲VNDA Articles Average Week Remove Ads Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Geron News Today Innoviva News Today Myriad Genetics News Today Rigel Pharmaceuticals News Today Emergent BioSolutions News Today Verastem News Today Codexis News Today XOMA News Today Ironwood Pharmaceuticals News Today Sangamo Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VNDA Stock Free VNDA Stock Alerts